Can-Fite BioPharma Ltd.
CANFAMEXHealthcare● Active
$3.08
$-0.01(-0.32%)
Market Cap$1657040
P/E Ratio—
52W High$23.4
52W Low$2.83
Can-Fite BioPharma Ltd. (CANF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CANF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.41M | $0.67M | $0.74M | $0.81M | $0.85M |
| Cost of Revenue | $0.02M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.38M | $0.67M | $0.74M | $0.81M | $0.85M |
| Gross Margin %(computed) | 94.07% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $6.75M | $5.76M | $5.98M | $7.76M | $9.85M |
| G&A Expenses | $0.00M | $3.05M | $2.96M | $3.14M | $3.85M |
| Total Operating Expenses | $10.41M | $8.80M | $8.94M | $10.91M | $13.70M |
| Operating Income | ($10.03M) | ($8.13M) | ($8.20M) | ($10.10M) | ($12.84M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.29M | $0.29M | $0.51M | $0.22M | $0.02M |
| Interest Expense | $0.01M | $0.01M | $0.01M | $0.08M | $0.02M |
| Income Before Tax | ($9.91M) | ($7.88M) | ($7.63M) | ($10.17M) | ($12.62M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.36M | ($0.02M) |
| Net Income | ($9.91M) | ($7.88M) | ($7.63M) | ($10.17M) | ($12.60M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-12.03 | $-1.08 | $-1.80 | $-3.75 | $-9.00 |
| Wtd Avg Shares | 0.82M | 7.25M | 4.26M | 2.72M | 1.53M |
| EBITDA | ($10.00M) | ($8.12M) | ($8.18M) | ($10.08M) | ($12.83M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Can-Fite BioPharma Ltd. data
About Can-Fite BioPharma Ltd. (CANF) Income Statement
Can-Fite BioPharma Ltd. (CANF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CANF reported revenue of $0.00B, gross profit of $0.00B (gross margin 94.07%), and net income of ($0.01B) — a net profit margin of -2426.67%.
Frequently asked questions
CANF · 4 questionsCan-Fite BioPharma Ltd. (CANF) reported revenue of $0.00B for 2025, down 39.4% year-over-year.
CANF revenueCANF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08